Tarsus Pharmaceuticals Inc

NASDAQ:TARS  
22.43
-0.34 (-1.49%)
Regulatory, Other Pre-Announcement

Tarsus Pharmaceuticals Inc Announces Positive Results Of Saturn-1 Pivotal Trial Evaluating Tp-03 For The Treatment Of Demodex Blepharitis

Published: 06/21/2021 11:37 GMT
Tarsus Pharmaceuticals Inc (TARS) - Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating Tp-03 for the Treatment of Demodex Blepharitis.
Tarsus Pharmaceuticals Inc - Saturn-1 Phase 2b/3 Trial Met All Primary and Secondary Endpoints.
Tarsus Pharmaceuticals - Saturn-1 Phase 2b/3 Trial Showed Significant, Clinically Meaningful Outcomes With No Serious Treatment-related Adverse Events.
Tarsus Pharmaceuticals - Tp-03 Was Well Tolerated With Safety Profile Similar to Vehicle, There Were No Treatment-related Discontinuations.
Tarsus Pharmaceuticals Inc - Expects Topline Results for Saturn-2 Trial in Q1 2022.